Online Safety Community

Why does FDA think they can Regulate them, and why do others think they Cannot

This presentation will review the legal definition of medical device, and how it is applied by FDA to in vitro diagnostic tests. It will review the history of FDA interest in LDTs, and will describe the current situation with respect to Laboratory-developed tests. It will describe tests which have been cleared by FDA and those which have attempted clearance but not been cleared. It will discuss possible future actions by FDA and by the US laboratory community and assess their probability.

Why should you have attend While a few clinical laboratories have cleared their tests through 510(k), the assertion of jurisdiction over LDTs by FDA has not been welcomed by most clinical laboratories, and has yet to be tested in the courts. This 1 hour session will explore the reasons FDA has for claiming such jurisdiction, and the objections to FDAs' position articulated by the clinical laboratory community, and others.

It will describe the current situation, which has FDA withdrawing their draft guidance, and Congress, in a 2013 law, calling for review of any new LDT guidance developed by FDA, prior to its issuance. Will FDA wait until this requirement sunsets in 2017? Presently, no new guidance appears to be on the books for 2014. Will FDA attempt to "get around" the requirement by issuing guidance under a different name? This talk will describe the reasons for FDAs concern, the legal arguments pro and con FDAs assertion of jurisdiction, the position of IVD manufacturers of competitive products, the situation today, and some possible outcomes.

These are the areas covered in this session

  • Definition of medical device, (21 USC 321(h))and how it has been interpreted by FDA and the courts
  • "Enforcement Discretion" and how it has been applied to LDT regulation
  • Extent of CLIA 88 authority over LDT performance
  • Role of US Congress in answering the question of FDA authority
  • International (EU) approach to LDTs

These areas of Experts will be benefited by this session

  • QA Specialist
  • Complaint Coordinator
  • Regulatory Specialist
  • QA Manager
  • QA Trainer
  • All above in Medical Device companies

Anna Longwell has been a visiting lecturer in food and drug law at the University of Santa Clara school of law, a visiting lecturer in food law at the Institute of Agribusiness, University of Santa Clara School of Business, a visiting lecturer in regulatory topics at the Haas School of Business, UC Berkeley, and the UC Santa Cruz Extension (UCSC), and an instructor for the Food and Drug Law Institute (FDLI) internship program at Catholic University, Washington DC.

You may login to http://www.compliance4all.com/control/w_product/~product_id=501419LIVE

Views: 10

Comment

You need to be a member of Online Safety Community to add comments!

Join Online Safety Community

Take our poll!

Take our poll!

Latest Activity

Roger Steven posted a blog post

Working with Physician Extenders to increase efficiency and profitability

A Physician Extender is one who is not a physician, but is of a lesser qualification, who helps physicians by carrying out many activities usually carried out by physicians. As the name suggests, Physician Extenders work to supplement the functions of a physician and could take a considerable load off her shoulders. In…See More
16 hours ago
John Robinson posted a blog post

‘Synthetic lethality’ targets cancer cells by damaging vulnerable DNA

By designing small molecules that can “turn off” kinase enzymes stuck in the “on” position, they have managed to ward off cancer’s attack. More recently, scientists have focused on ways to help the body’s own immune cells seek and destroy cancer cells.Enter the concept known as synthetic lethality. Researchers have long known that a cancer cell hobbling along with one broken gene is vulnerable. Knock out another key gene, they have discovered, and the cell will topple.The notion of killing…See More
17 hours ago
Adam Fleaming posted blog posts
17 hours ago
Training Doyens posted events
18 hours ago

Forum

Risk Management Solutions

Risk is defined as the potential hazard, harm or side effect of an activity. Almost all activities come with some or another form of risk, which needs to be mitigated or eliminated. Risk management…Continue

Tags: risk, Banking, management, healthcare, Process

Started by John Robinson yesterday.

Occupational Health and Safety 4 Replies

Health and safety are important aspects of an organisation’s smooth and effective functioning.  Did you know that workplace health & safety injuries cost Australian businesses over $60 billion…Continue

Tags: Safety, and, Health, Occupational

Started by WHS Solutions. Last reply by John Robinson on Monday.

Introduction to PEGA-PRPC

Pega/PRPC is a popular rules engine and BPM tool from Pega systems that is gaining good market share among large corporations. Architects and developers build the Pega/PRPC instance while…Continue

Tags: training, course, online, pega

Started by Soujanya Naganuri Oct 6.

Introduction to PEGA-PRPC

Pega/PRPC is a popular rules engine and BPM tool from Pega systems that is gaining good market share among large corporations. Architects and developers build the Pega/PRPC instance while…Continue

Tags: training, course, online, pega

Started by Soujanya Naganuri Oct 6.

Introduction to PEGA-PRPC

Pega/PRPC is a popular rules engine and BPM tool from Pega systems that is gaining good market share among large corporations. Architects and developers build the Pega/PRPC instance while…Continue

Tags: training, course, online, pega

Started by Soujanya Naganuri Oct 6.

Badge

Loading…

© 2017   Created by Safety Community.   Powered by

Badges  |  Report an Issue  |  Terms of Service